Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Century Therapeutics (IPSC) Operating Income (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Operating Income for 4 consecutive years, with -$5.4 million as the latest value for Q4 2025.

  • Quarterly Operating Income rose 85.5% to -$5.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.0 million through Dec 2025, up 98.54% year-over-year, with the annual reading at -$2.0 million for FY2025, 98.53% up from the prior year.
  • Operating Income for Q4 2025 was -$5.4 million at Century Therapeutics, up from -$36.1 million in the prior quarter.
  • The five-year high for Operating Income was $74.2 million in Q1 2025, with the low at -$43.8 million in Q4 2023.
  • Average Operating Income over 4 years is -$26.3 million, with a median of -$34.7 million recorded in 2024.
  • The sharpest move saw Operating Income plummeted 31.39% in 2023, then skyrocketed 336.92% in 2025.
  • Over 4 years, Operating Income stood at -$33.3 million in 2022, then tumbled by 31.39% to -$43.8 million in 2023, then rose by 14.8% to -$37.3 million in 2024, then soared by 85.5% to -$5.4 million in 2025.
  • According to Business Quant data, Operating Income over the past three periods came in at -$5.4 million, -$36.1 million, and -$34.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.